AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions and listings of claims in the

application.

Claim 1 (currently amended): A method of isolating and culturing mesenchymal

stem cells from cryopreserved umbilical cord blood, comprising the steps of:

thawing cryopreserved umbilical cord blood and adding aMEM (alpha-

minimum essential medium) alpha-minimum essential medium (αMEM) thereto,

followed by centrifugation to harvest monocytes;

isolating CD133 positive cells from the obtained monocytes; and

subjecting suspending the isolated cells into suspension culture in the with

α-MEM containing at least one of Stem Cell Factor, GM-CSF (granulocyte-macrophage

eolony-stimulating factor) granulocyte-macrophage colony-stimulating factor (GM-CSF),

G-CSF (granulocyte colony-stimulating factor) granulocyte colony-stimulating factor (G-

CSF), HL-3 (interleukin-3) interleukin-3 (IL-3) and HL-6 (interleukin-6) interleukin-6 (IL-

6).

Claim 2 (original): The method as set forth in claim 1, wherein the umbilical cord

blood is added with 2-fold volume of the aMEM, overlapped on Ficoll-Hypaque, and

then subjected to centrifugation to harvest monocytes.

-2-

Response to May 19, 2008 Office Action

Claim 3 (currently amended): The method as set forth in claim 1, wherein the

Docket No. 36470-231117

aMEM for culturing monocytes further comprises at least one of an antibiotic, an anti-

fungal agent, glutamine and fetal bovine serum.

Claim 4 (new): The methods set forth in claim 1 wherein the culture in the aMEM

contains Stem Cell Factor, GM-CSF, G-CSF, IL-3 and IL-6.

Claim 5 (new): The method as set forth in claim 3, wherein the aMEM for

culturing monocytes further comprises an antibiotic, an anti-fungal agent, glutamine and

fetal bovine serum.

-3 -